Aditxt Inc :Aditxt, Inc. Enters Into Definitive Agreement To Acquire Evofem Biosciences, Inc., Creator Of Phexxi®, The First And Only Fda-Approved Hormone-Free Contraceptive Gel, To Address Diverse Reproductive Health Needs Of Women Globally.Aditxt Inc - Proposed Deal For Having An Aggregate Amount Of Approximately $100 Million.Aditxt Inc - Transaction Is Intended To Create Significant Strategic Advantages For Both Companies.Aditxt Inc - Boards Of Directors Of Both Companies Have Unanimously Approved Transaction.Aditxt Inc - Assumed Evofem'S Senior Secured Debt That Was Issued To Investor Under Securities Purchase And Security Agreement Dated April 2020.Aditxt- Agreed To Provide $3.0 Million Loan To Evofem Between Date Of Signing Of Agreement And Closing And To Cover Evofem'S Legal Costs Related To Deal.Aditxt Inc - At Deal Closing, Holders Of Evofem'S Common Stock Will Exchange Their Shares For An Aggregate Of 610,000 Shares Of Aditxt Common Stock.Aditxt Inc - After Closing, Evofem Will Be A Wholly Owned Subsidiary Of Aditxt.Aditxt Inc - Evofem Will Continue To Be Led By Saundra Pelletier, Chief Executive Officer Of Evofem, And Current Management Team.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments